| Complementary and Alternative Medicine |
1 |
1 |
| Heart Failure (HF) |
0 |
1 |
| Cardiovascular Risk Management |
0 |
0.85 |
| Hypertension |
0 |
0.83 |
| Heart |
0 |
0.67 |
| Cardiovascular Imaging |
0 |
0.61 |
| Clinical Guidelines |
0 |
0.44 |
| Receptors |
0 |
0.37 |
| Angiotensin II Receptor Blockade |
0 |
0.31 |
| Traditional Chinese Medicine |
0 |
0.99 |
| Ejection Fraction |
0 |
0.98 |
| Beta-Adrenergic Agonist |
0 |
0.15 |
| Cardiovascular disease |
0 |
0.15 |
| Europe |
0 |
0.15 |
| Healthcare and Medical Technology |
0 |
0.08 |
| Myocardial Infarction (MI) |
0 |
0.08 |
| ACE Inhibitor |
0 |
0.07 |
| B-Type Natriuretic Peptide |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| Diuretics |
0 |
0.07 |
| Hospital |
0 |
0.07 |
| New York |
0 |
0.07 |
| Renin-Angiotensin System |
0 |
0.07 |